 |
» |
|
|
|
Knowledge Management Challenges in Large-Scale R&D
David Hodgson, Global Head, Group Knowledge Exchange, Roche Pharmaceuticals
How agile software engineering, in-silico science, knowledge technologies and leadership turned our internal customers from doubting critics into raving (happy) fans.
Our Informatics function reports to the president of research and accountable for delivering all the information solutions required for innovation in drug discovery research. Internal focus, bureaucracy and morale were threatening to jeopardize our value to the larger organization.
By innovating how we develop software and re-focusing on projects closest to the highest priorities of research we're vastly improving our impact, value and reputation with our research colleagues.
This presentation is not available
|
Body of Millions, Target of One: Better Patient Health Through a Connected Industry Ecosystem
Jason Burke, Worldwide Director of Health and Life Sciences, SAS
The health and life sciences ecosystem is in a state of gradual convergence around patients. While independent market segments - providers, payers, pharmaceutical firms - remain focused on their respective business challenges, a growing community is recognizing that the challenges each market segment faces can only be solved through working in partnership with the other market segments.
The historical barriers over cost transference and pricing protection must give way to a focus on quality of patient care. Current trends in patient/drug safety, disease management, patient records, reporting, and information system interoperability all point towards a future where health outcomes can be better managed by leveraging the growing repositories of health-related information available within the ecosystem. And whereas 2008 shows a priority around business intelligence, the future of healthcare will be based on advanced analytics that revolve around the patient, leveraging the information from millions of individuals to help target the right treatment to each individual.
This presentation is not available
|
Real-Time Clinical Trials
John Varaklis, Head of Operations and Innovation for Transitional Medicine, Novartis Pharmaceuticals Corporation
Industry experts, analysts and executives alike acknowledge the need to significantly reduce the time and costs associated with bringing new medicines to market. This presentation will discuss how the biopharmaceutical industry is successfully using new technologies in clinical trials to monitor patients on a real-time basis. The presentation will focus on transformational technological changes and how the biopharmaceutical industry has productively reshaped its business strategies enabling new approaches to trial design, improved safety and efficacy.
|
Digital Hospital Case Study
Bjørn Magne Eggen M.D., Ph.D, Director of Medicine and Strategy, Akershus University Hospital
The Akershus University Hospital presently builds a complete new hospital, 137,000 square meters (1.5 mill sq. feet), close to the present location (www.nyeahus.no and www.ahus.no). In addition the hospital invests heavily in the most up-to-date technology (e.g. ICT, diagnostic imaging, electronic patient record with speech recognition). In order to prepare for the new hospital facilities, the hospital made several large projects (in total 23) on organisational development – and has changed the organisational structure prior to moving into the new hospital (which will take place in October 2008). The presentation will outline the process of developing the organisation, the implementation of all the changes needed, and the present teaching of all staff members – quoted as “your key to the new hospital”.
|
SIMS Sets SAIL
Jim Forbes, Chief Technology Officer, University Health Network, Toronto Canada
Shared Information Management Services (SIMS) offers an innovative approach to Healthcare transformation in the Greater Toronto Area (GTA). SIMS is a volunteer collaborative of Healthcare delivery agencies including participants from the Acute Care Sector, Rehab Sector, Long-term care Agencies and Community Care Services. Partners work strategically to design, develop and implement foundational infrastructure such as Shared Application Integration Layer (SAIL) and common applications to support Healthcare transformation.
SAIL is the cornerstone to the infrastructure needed to support innovation and transformation of the healthcare system in the GTA.
|
Avoiding Unintended Consequences of Health IT Implementations
Chris Longhurst, MD, MS, FAAP, Clinical Assistant Professor of Pediatrics, Stanford School of Medicine, Physician Lead, Clinical Informatics, Lucile Packard Children’s Hospital
Chris Longhurst, MD, MS, FAAP, Clinical Assistant Professor of Pediatrics, Stanford School of Medicine, Physician Lead, Clinical Informatics, Lucile Packard Children’s Hospital
Although many experts view CPOE as a transformational tool in the journey toward high reliability, recent research highlights the unintended consequences of suboptimal EMR implementations. In this talk, we will expand the concept of highly reliable healthcare, review the recent literature of unintended consequences, and share practical, evidence-based strategies for EMR implementation.
|
|
|
Connectivity: Lynchpin of the Molecular Medicine Revolution
Kenneth H. Buetow, Ph.D., NCI Associate Director for Bioinformatics and Information Technologies
The clinical promise of molecular medicine – to deliver preventive, preemptive, and personalized care – requires a seamless connectivity along every step of the continuum from discovery through biobanking through imaging and into clinical development and clinical care. The traditional barriers to such connectivity were technical, financial, and perhaps most importantly, cultural. The National Cancer Institute has addressed these challenges with the successful development and implementation of the caBIGTM (cancer Biomedical Informatics Grid) initiative, which provides standards, infrastructure, and tools to link the entire cancer research community. Close to 60 NCI-designated and Community Cancer Centers across the United States are now adopting caBIGTM, and caBIGTM infrastructure is spreading to other disease areas in the US and internationally. This presentation will provide an update on this unprecedented system, and describe how the “BIG” system is enabling interoperability – and the benefits of faster and smarter research - among previously disparate parts of the biomedical enterprise.
|
Future Models in Product Development: An HIV Diagnostic and Therapeutic Case Study
Michael Williams, Therapeutic Area Commercial Lead for Infectious Disease, Pfizer
William Young, Chief Executive Officer, Monogram Biosciences
|
Translational Infrastructure for Facilitating Research and Practice of Personalized Genomic Medicine
Charis Eng, MD, PhD, Genomic Medicine Institute, Center for Personalized Genetic, Healthcare, Lerner Research Institute, and Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
Personalized medicine has been in existence for a long time. For example, ABO typing for blood transfusions is consistent with the practice of personalized healthcare. However with the recent explosion in the knowledge of genomics and other –omics as well as the technological know-how, the fine tuning of –omics-based personalized healthcare is here. While all this provides content, context is lagging behind. Without context, content is meaningless for practicing personalized medicine.
One important way to consolidate content and context is to set about rigorously integrating –omics data with well annotated clinical phenotypic data (phenomics). The Cleveland Clinic Genomic Medicine Institute (GMI) serves as the expert base for the principles and practice of genomic medicine as a single platform for research, academic clinical care, outreach and education, ultimately directed at genomics-based personalized healthcare. Thus, GMI research focuses on translational and clinical human genetics and genomics (including epigenomics and proteomics), which would be eminently applicable to the routine clinical arena. Coordinating and then integrating genomics (and other –omics) research across many disciplines such that inter-disciplinary research and healthcare are being enhanced entails significant organizational and informatics resources, including management of study subject data, family and medical history, research specimens, genetic and other molecular and functional analytical results. This focus of this talk will highlight such translational projects in progress, with an example from our inter-disciplinary PTEN studies, including the challenges in handling patient specimens and annotation for biobanking, moving from hypothesis generation to hypothesis testing to analysis and manipulation and the utility of bioinformatics for support of these efforts.
|
|
|
|
|
The Global Ageing and Social Care Market: What are the Technological Challenges in the Fastest Growing Market in the World
Stewart Maxwell, Chief Executive Officer, Cerrus International, UK
The ageing and social care markets are the fastest growing markets in the world and to-date have been largely neglected by IT providers. With an almost global mandate by Governments to keep people into the community rather than moving them into Hospitals, the world faces a fast growing and high level of people in the ageing and social care arena without the technological infrastructure needed to manage the processes. This presentation will discuss the current situation in the global ageing and social care market, recent trends and challenges. Topics to be discussed will include ageing cities, the continuum of care, the need for system integration between health and social care systems and the role of information technology in managing a corporate or national social care provision. Case studies will be provided together with an overview on the research and steps Cerrus has undertaken to meet the challenges in the European and Asia markets.
|
Prospects for Defeating Aging Altogether
Dr Aubrey de Grey, Biomedical Gerontologist, Chief Science Officer, Methuselah Foundation Editor-in-Chief “Rejuvenation Research
It may seem premature to be discussing approaches to the effective elimination of human aging as a cause of death at a time when essentially no progress has yet been made in even postponing it.
However, two aspects of human aging combine to undermine this assessment. The first is that aging is happening to us throughout our lives but only results in appreciable functional decline after four or more decades of life: this shows that we can postpone the functional decline caused by aging arbitrarily well without knowing how to prevent aging completely, but instead by increasingly thorough molecular and cellular repair. The second is that the typical rate of refinement of dramatic technological breakthroughs is rather reliable (so long as public enthusiasm for them is abundant) and is fast enough to change such technologies (be they in medicine, transport, or computing) almost beyond recognition within a natural human lifespan. In this talk I will explain, first, why (presuming adequate funding for the initial preclinical work) therapies that can add 30 healthy years to the remaining lifespan of healthy 55-year- olds may arrive within the next few decades, and, second, why those who benefit from those therapies will very probably continue to benefit from progressively improved therapies indefinitely and thus avoid debilitation or death from age-related causes at any age.
|
Political Implications of Personalized Medicine
John Glaser, Ph.D., Vice President and Chief Information Officer, Partners HealthCare
Personalized medicine has the potential to effect significant improvements in care safety, quality and utilization. However the broad adoption of personalized medicine raises complex, ethical, reimbursement, care practice, privacy and regulatory challenges. This presentation will explore these broad political and societal ramifications.
|
|
|
|
|
|
|
Relating Clinical and Genomic Medicine Using Translational Bioinformatics
Atul Butte, MD, PhD, Assistant Professor, Stanford University School of Medicine, Director, Center for Pediatric Bioinformatics, Lucile Packard Children’s Hospital
With the end of the United States NIH budget doubling and completion of the Human Genome Project, there is a need to translate genome-era discoveries into clinical utility. The difficulties in making bench-to-bedside translations have been described: comprehensive molecular studies on patients are expensive, and hospitals are not phenotypers. The nascent field of translational bioinformatics may help. The past 10 years have led to a variety of measurements tools in molecular biology that are nearly-comprehensive in nature, like microarrays across all known genes, and genome scans across an individual’s DNA. But a richer model of disease will need more than just the input of genetics; the variance in patients’ outcomes with a disease is also a function of their environment and our variance in delivering care as health-care providers. With more hospitals moving toward capturing more elements of clinical care into electronic repositories, we can start to use electronic health record data, such as physician orders, medications delivered, and laboratory tests measured, to model basic systems biological processes in disease. In work spanning from the HP partnership with the Harvard Partners Center for Genetics and Genomics to the new pilot partnership with the Lucile Packard Children’s Hospital, I will show how clinical and molecular data can finally be joined, enabling us to rethink the nature of disease itself.
|
Life Science Supply Chain Evolution: Racing Toward the Next-Generation of Sales and Supply
Erik Newmark, Research Manager, Health Industry Insights, IDC
Technology is quickly rewriting the ground rules of the commercial life science landscape. Process analytical technologies intend to modernize drug manufacturing and improve quality assurance. Drug pedigrees, item level serialization, RFID, and 852/867 data aim to revolutionize supply chain management and drastically reduce revenue leakage from inefficient chargebacks and product returns.
Inventory management agreements, fee-for-service agreements, and cross-border drug trade continue to reshape the ways manufacturers and distributors interact. And IT outsourcing is quickly becoming core to industry wide cost-reduction strategies. All of these topics and more will be discussed as we look at how innovation is driving the market towards the next generation of the commercial life sciences.
|
The EMR Journey – A Chief Information Officer’s Perspective
Malcolm P Thatcher, Chief Information Officer, Mater Health Services Brisbane, Australia
Healthcare is a knowledge industry that relies on the fusion of information and science to deliver effective and often complex care to patients. Healthcare is also a sector traditionally tethered to managing large volumes of paper which is inherently inefficient and not easily harvested for knowledge. Moving away from paper to an Electronic Medical Record is a massive change for a care delivery organisation and requires typically unforeseen commitment, courage and conviction. Four years ago with the appointment of their first Chief Information Officer, Mater Health Services made a commitment to progress a health IT agenda. In hindsight the organisation probably didn’t fully understand what it was committing to or how long the journey would really be. This presentation provides a reflection on Mater’s journey thus far which currently involves the enterprise deployment of a clinical portal which is fundamentally changing how clinicians approach longitudinal health information. This presentation will discuss Mater’s holistic Smart Hospital Strategy, the lessons learned and those elements that have proved to be critical success factors in the Mater’s achievements thus far.
Mater Health Services Brisbane (MHS) was established in 1906 by the Sisters of Mercy to provide holistic healthcare to those most in need within the community. Today MHS comprises tertiary teaching hospitals within a seven hospital group totaling 1,000 beds. With around 6,000 staff MHS provides over 500,000 occasions of service to the |
|
|
|
|
Versija spausdinimui
